16:26 , Jan 12, 2018 |  BC Week In Review  |  Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
23:54 , Jan 9, 2018 |  BC Extra  |  Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
19:58 , Aug 4, 2017 |  BC Week In Review  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
23:20 , Aug 3, 2017 |  BC Extra  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
07:00 , Aug 20, 2007 |  BioCentury  |  Regulation

Considering all the Factors

Recent developments in the EU have shed some light on two important factors in the economics of biosimilars - how abbreviated a clinical path they can follow, and whether they will be regarded as interchangeable...
02:15 , Aug 1, 2007 |  BC Extra  |  Politics & Policy

EMEA adding recombinant Factor VIII warning

EMEA said it will add a warning of neutralizing antibodies to the summary of product characteristics for all recombinant Factor VIII (rFVIII) products marketed in the EU for hemophilia A. The warning follows an agency...
07:00 , May 28, 2002 |  BC Week In Review  |  Clinical News

Recombinant Factor VIII: Phase III

BAX said preliminary data from 30 patients in a double-blind Phase III trial showed its recombinant Factor VIII prepared without the use of human- or animal-derived additives was bioequivalent to Recombinate Factor VIII. BAX...
07:00 , May 21, 2002 |  BC Extra  |  Clinical News

Baxter Phase III hemophilia A data

BAX said preliminary data from a Phase III trial showed its recombinant antihemophilic Factor VIII prepared without the use of human- or animal-derived additives was bioequivalent to Recombinate recombinant antihemophilic factor. BAX said that all...
08:00 , Nov 20, 2000 |  BC Week In Review  |  Clinical News

Recombinant Factor VIII: Began Phase III trial

Baxter Healthcare Corp. (BAX), Deerfield, Ill.   Product: Recombinant Factor VIII   Business: Blood products/substitutes   Therapeutic category: Thrombolysis/Thrombosis, Enzyme replacement   Target: Clotting factors   Description: Recombinant Factor VIII protein   Indication: Treat hemophilia A   Status: BAX began an international...